Enjoy complimentary customisation on priority with our Enterprise License!
The infectious enteritis treatment market share is expected to increase by USD 403.92 million from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 5.09%. This infectious enteritis treatment market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. The infectious enteritis treatment market report also offers information on several market vendors, including Abbott Laboratories, Almirall SA, Cipla Ltd., Zydus Lifesciences Ltd., F. Hoffmann La Roche Ltd., Galderma SA, GlaxoSmithKline Plc, Hetero Healthcare Ltd., Mayne Pharma Group Ltd., Medimetriks Pharmaceuticals Inc., Merck KGaA, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Tolmar Pharmaceuticals Inc., and Viatris Inc. among others. Furthermore, this report extensively covers infectious enteritis treatment market segmentation by route of administration (oral and injectables) and geography (North America, Europe, Asia, and Rest of World (ROW)).
Download the Free Report Sample to Unlock the Infectious Enteritis Treatment Market Size for the Forecast Period and Other Important Statistics
The increasing geriatric population is notably driving the infectious enteritis treatment market growth, although factors such as adverse effects associated with infectious enteritis treatment may impede market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the infectious enteritis treatment industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.
Key Infectious Enteritis Treatment Market Driver
One of the key factors driving the global infectious enteritis treatment market growth is the increasing geriatric population in countries, such as Japan, Italy, and the US. For instance, according to the United Nations (UN) Department of Economic and Social Affairs, the population division of the geriatric population (persons aged 65 or over) was 702.9 million in 2019, which will become 727 million in 2020. Similarly, the geriatric population in India will increase by 41% over the next decade to touch 194 million in 2031. This increase in the percentage of the geriatric population around the globe is increasing the demand for the treatment of hospital-acquired infections around the world, which will work as a driver for the infectious enteritis treatment market during the forecast period.
Key Infectious Enteritis Treatment Market Trend
Burgeoning demand for antivirals is one of the key infectious enteritis treatment market trends that is expected to impact the industry positively in the forecast period. One can treat viral gastroenteritis by replacing lost fluids and electrolytes to prevent dehydration. In some cases, over-the-counter (OTC) drugs, such as loperamide (Imodium) and bismuth subsalicylate (Pepto-Bismol, Kaopectate), may also help relieve the symptoms due to viral gastroenteritis. Moreover, doctors also avoid prescribing antibiotics to treat viral gastroenteritis since antibiotics are not efficient against viral infections. As of now, two vaccines, which infants receive by mouth, are approved to protect against rotavirus infections, i.e., RotaTeq and Rotarix. Such factors are expected to support the market growth in the coming years.
Key Infectious Enteritis Treatment Market Challenge
One of the key challenges to the global infectious enteritis treatment market growth is the adverse effects associated with infectious enteritis treatment. Infectious enteritis causes diarrhea and associated fluid and electrolyte losses. Maldigestion and malabsorption are the dominant underlying pathophysiologic mechanisms; hence, intravenous therapy is more effective (at least initially) at correcting the electrolyte imbalances and fluid loss compared with oral administration. The crystalloids and colloids fluids should be considered as part of the fluid therapy. However, sometimes the treatment of infectious enteritis with these fluids or any other medication such as penicillin, cephalosporin, antifolate or sulfa combinations, nitroimidazole, glycopeptide, and monobactam antibiotics would further cause various side effects due to the historic allergy of the patients. Such factors are expected to negatively impact the market growth during the forecast period.
This infectious enteritis treatment market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.
Technavio categorizes the global infectious enteritis treatment market as a part of the global pharmaceuticals market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the infectious enteritis treatment market during the forecast period.
The report analyzes the market's competitive landscape and offers information on several market vendors, including:
This statistical study of the infectious enteritis treatment market encompasses successful business strategies deployed by the key vendors. The infectious enteritis treatment market is fragmented and the vendors are deploying growth strategies such as geographical expansion, product portfolio expansion, and product innovation to compete in the market.
To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
The infectious enteritis treatment market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.
Our report provides extensive information on the value chain analysis for the infectious enteritis treatment market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.
For more insights on the market share of various regions Request for a FREE sample now!
37% of the market's growth will originate from North America during the forecast period. US and Canada are the key markets for infectious enteritis treatment in North America. Market growth in this region will be faster than the growth of the market in Rest of World (ROW).
The significant increase in foodborne illnesses in countries such as the US will facilitate the infectious enteritis treatment market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.
To gain further insights on the market contribution of various segments Request for a FREE sample
The infectious enteritis treatment market share growth by the oral segment will be significant during the forecast period. The rapid action of oral rehydration therapy on patients will drive the growth of the market in focus through this segment in the coming years. For instance, it has also been observed that zinc, in conjunction with ORS, is effective in reducing acute diarrhea by 15%-25%.
This report provides an accurate prediction of the contribution of all the segments to the growth of the infectious enteritis treatment market size and actionable market insights on post COVID-19 impact on each segment.
Infectious Enteritis Treatment Market Scope |
|
Report Coverage |
Details |
Page number |
120 |
Base year |
2021 |
Forecast period |
2022-2026 |
Growth momentum & CAGR |
Accelerate at a CAGR of 5.09% |
Market growth 2022-2026 |
$ 403.92 million |
Market structure |
Fragmented |
YoY growth (%) |
3.52 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 37% |
Key consumer countries |
US, Canada, Germany, UK, and China |
Competitive landscape |
Leading companies, Competitive strategies, Consumer engagement scope |
Key companies profiled |
Abbott Laboratories, Almirall SA, Cipla Ltd., Zydus Lifesciences Ltd., F. Hoffmann La Roche Ltd., Galderma SA, GlaxoSmithKline Plc, Hetero Healthcare Ltd., Mayne Pharma Group Ltd., Medimetriks Pharmaceuticals Inc., Merck KGaA, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Tolmar Pharmaceuticals Inc., and Viatris Inc. |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Five Forces Analysis
5 Market Segmentation by Route of Administration
6 Customer Landscape
7 Geographic Landscape
8 Drivers, Challenges, and Trends
9 Vendor Landscape
10 Vendor Analysis
11 Appendix
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.